Light-controllable cell-membrane disturbance for intracellular delivery-Reference-Cited by-同舟云学术

Light-controllable cell-membrane disturbance for intracellular delivery

Published:2024 Issue:17 Volume:12 Page:4138-4147
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Huo Wenting¹,Miki Koji¹^ORCID,Mu Huiying¹^ORCID,Osawa Takashi²,Yamaguma Harumi³,Kasahara Yuuya³^ORCID,Obika Satoshi²⁴^ORCID,Kawaguchi Yoshimasa⁵^ORCID,Hirose Hisaaki⁵^ORCID,Futaki Shiroh⁵^ORCID,Miyazaki Yusuke⁶^ORCID,Shinoda Wataru⁶^ORCID,Akai Shuji²^ORCID,Ohe Kouichi¹^ORCID

Affiliation:

1. Department of Energy and Hydrocarbon Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, 615-8510, Japan

2. Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan

3. Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan

4. Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, 565-0871, Japan

5. Institute for Chemical Research, Kyoto University, Kyoto, 611-0011, Japan

6. Research Institute for Interdisciplinary Science, Okayama University, Okayama, 700-8530, Japan

Abstract

A light-controllable delivery method based on the tetraphenylethene derivative was developed to improve the intracellular delivery of charged molecules. It does not require chemical modification of drugs and is applicable to a variety of cell lines.

Funder

Japan Society for the Promotion of Science

Uehara Memorial Foundation

Asahi Glass Foundation

Otsuka Toshimi Scholarship Foundation

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/TB/D3TB02956E

Reference45 articles.

1. Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization

2. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy

3. RNA therapeutics: beyond RNA interference and antisense oligonucleotides

4. Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases

5. Knocking down disease: a progress report on siRNA therapeutics